Key points

In infants

• The mandatory meningococcal ACWY vaccination program, implemented on January 1, 2025, in response to the rise in invasive meningococcal W and Y infections, resulted in high vaccination coverage by 2025, with 91% of infants having received the first dose of the vaccine. Among those aged 21 months (born before 2025), 80% had received at least one dose of the tetravalent ACWY vaccine, compared to 91% in 2024 for the monovalent C vaccine. It should be noted that a vaccination schedule for infants initiated with a monovalent C vaccine must be continued with a tetravalent ACWY vaccine.
• Regarding meningococcal B, for which vaccination also became mandatory in 2025, regional vaccination coverage with the full schedule at 21 months reached 71%, an increase of 10 percentage points compared to 2024. The lowest coverage was in the department of Sarthe at 62%.
• Vaccination coverage for other mandatory infant vaccinations reached levels approaching the 95% target set by the World Health Organization (WHO). In light of the resurgence of measles virus circulation in France in 2024, it is important to note that coverage with two doses of the Measles-Mumps-Rubella (MMR) vaccine must exceed 95% to interrupt the circulation of the virus, which can lead to deaths among vulnerable individuals. Verifying vaccination status and keeping records up to date remain essential, for both children and adults.

In adolescents and young adults

• Given the potential severity and increased frequency of invasive meningococcal infections during adolescence, vaccination against meningococcal ACWY is recommended for adolescents, with catch-up vaccination for young adults. In 2025, only 19% of 11- to 14-year-olds and 9% of 15- to 24-year-olds had received a dose of the vaccine. Vaccination efforts must be stepped up in these age groups; to this end, it was integrated into vaccination campaigns conducted in middle schools in 2026. Improved vaccination coverage will enable herd immunity and reduce the circulation of meningococci in other age groups.
• Vaccination coverage against human papillomavirus (HPV) infections—with the full series completed by age 16—increased to 63% among girls and 45% among boys, and the gap between the two narrowed. It remains insufficient to reduce the incidence of associated cancers. The target set by the 10-year cancer control strategy is to reach 80% by 2030. Efforts must continue, building on vaccination campaigns in middle schools and reinforcing the message that vaccinating boys is just as essential as vaccinating girls, contributing to equitable and sustainable protection.

Vaccination Uptake

According to the 2024 Santé publique France Barometer, vaccination uptake in general remained high in the region, particularly among young people, with 88% of 18- to 25-year-olds expressing support—the highest proportion in mainland France.